At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 41 enrolled
Drug / intervention
Gemcitabine combined with Aptinib and Toripalimabdrug
Likely dose
Gemcitabine combined with Aptinib and Toripalimab 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 1 clinical trial evaluating Gemcitabine combined with Aptinib and Toripalimab for Nasopharyngeal Carcinoma. Targeting 41 participants across 1 site.
Detailed Summary
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
2020202120222023202420252026
Enrollment StartJun 2019
First PostedAug 2019
Primary CompletionApr 2022
Study CompletionApr 2024
TodayJul 2026
First PostedAug 29, 2019
Enrollment StartJun 8, 2019
Primary CompletionApr 1, 2022
Study CompletionApr 1, 2024
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 6.8 years ago
Interventions
Gemcitabine combined with Aptinib and Toripalimabdrug
Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles. Apatinib for oral administration, 250mg, once a day. Apatinib maintenance. Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance.